Home > Back to Publisher > Report Information

United Arab Emirates In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017

Global Markets Direct
January 23, 2012
144 Pages - SKU: GMD6775781

Abstract Table of Contents Search inside this report Related Reports

Countries covered: United Arab Emirates

United Arab Emirates In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017

Summary

”United Arab Emirates In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017”, a new report by Global Markets Direct, provides key market data on the United Arab Emirates In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct’s team of industry experts.

Scope

Market size and company share data for In Vitro Diagnostics market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
2010 company shares and distribution shares data for each of the seven market categories.
Global corporate-level profiles of key companies operating within the United Arab Emirates In Vitro Diagnostics market.
Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Beckman Coulter, Inc., Abbott Laboratories, Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.

Reasons to buy

Develop business strategies by identifying the key market categories and segments poised for strong growth.
Develop market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the United Arab Emirates In Vitro Diagnostics competitive landscape.
Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

1 Table of Contents: 1.1 List of Tables; 1.2 List of Figures
2 Introduction: 2.1 What is This Report About?
3 In Vitro Diagnostics In United Arab Emirates: 3.1 In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, 2003-2017; 3.2 In Vitro Diagnostics, United Arab Emirates, Company share (2009-2010)
4 Clinical Chemistry In United Arab Emirates: 4.1 Clinical Chemistry Overall Revenue (2003-2017); 4.2 Clinical Chemistry Distribution Share (2009-2010); 4.3 Clinical Chemistry, United Arab Emirates, Company share (2009-2010)
5 Genetic Testing In United Arab Emirates: 5.1 Genetic Testing Overall Revenue (2003-2017); 5.2 Genetic Testing Distribution Share (2009-2010); 5.3 Genetic Testing, United Arab Emirates, Company share (2009-2010)
6 Haematology In United Arab Emirates: 6.1 Haematology Overall Revenue (2003-2017); 6.2 Haematology Distribution Share (2009-2010); 6.3 Haematology, United Arab Emirates, Company share (2009-2010)
7 Histology And Cytology In United Arab Emirates: 7.1 Histology And Cytology Overall Revenue (2003-2017); 7.2 Histology And Cytology Distribution Share (2009-2010); 7.3 Histology And Cytology, United Arab Emirates, Company share (2009-2010)
8 Immuno Chemistry In United Arab Emirates: 8.1 Immuno Chemistry Overall Revenue (2003-2017); 8.2 Immuno Chemistry Distribution Share (2009-2010); 8.3 Immuno Chemistry, United Arab Emirates, Company share (2009-2010)
9 Infectious Immunology In United Arab Emirates: 9.1 Infectious Immunology Overall Revenue (2003-2017); 9.2 Infectious Immunology Distribution Share (2009-2010); 9.3 Infectious Immunology, United Arab Emirates, Company share (2009-2010)
10 Microbiology Culture In United Arab Emirates: 10.1 Microbiology Culture Overall Revenue (2003-2017); 10.2 Microbiology Culture Distribution Share (2009-2010); 10.3 Microbiology Culture, United Arab Emirates, Company share (2009-2010)
11 Overview of Key Companies in United Arab Emirates In Vitro Diagnostics Market: 11.1 F. Hoffmann-La Roche Ltd.; 11.2 Siemens Healthcare; 11.3 Beckman Coulter, Inc.; 11.4 Abbott Laboratories; 11.5 Ortho-Clinical Diagnostics Inc.; 11.6 bioMerieux S.A.; 11.7 The Elitech Group; 11.8 Alere Inc.; 11.9 Becton, Dickinson and Company; 11.10 DiaSorin S.p.A; 11.11 Bio-Rad Laboratories, Inc.; 11.12 Mindray Medical International Limited; 11.13 Phadia AB; 11.14 Thermo Fisher Scientific Inc.; 11.15 HORIBA, Ltd.; 11.16 Sysmex Corporation; 11.17 Grifols, S.A.; 11.18 Qiagen N.V.; 11.19 Gen-Probe Incorporated; 11.20 DIAGNOSTICA STAGO, Inc.; 11.21 Immucor, Inc.; 11.22 PerkinElmer, Inc.; 11.23 Life Technologies Corporation; 11.24 Hologic, Inc.; 11.25 Chembio Diagnostic, Inc.
12 APPENDIX: 12.1 Global Markets Direct Research Methodology; 12.2 Definitions of Markets Covered in the Report; 12.3 Secondary Research; 12.4 Primary Research; 12.5 Models; 12.6 Forecasts; 12.7 Expert Panel Validation; 12.8 Currency Conversion; 12.9 Contact Us; 12.10 Disclaimer
1.1 List of Tables: Table 1: In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, 2003-2017; Table 2: In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, Historic, 2003-2010; Table 3: In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, Forecast, 2010-2017; Table 4: In Vitro Diagnostics, United Arab Emirates, Company share by Revenue ($m), USD Actual, 2009-2010; Table 5: Clinical Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 6: Clinical Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 7: Clinical Chemisty Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 8: Clinical Chemisty Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 9: Urine Analysis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 10: Urine Analysis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 11: Clinical Chemistry, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 12: Clinical Chemistry, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010; Table 13: Genetic Testing, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 14: Genetic Testing, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 15: Genetic Testing, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 16: Genetic Testing, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010; Table 17: Haematology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 18: Haematology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 19: Haematology Reagents, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 20: Haematology Reagents, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 21: Immunohaematology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 22: Immunohaematology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 23: Haemostasis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 24: Haemostasis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 25: Haematology Rapid Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 26: Haematology Rapid Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 27: Haematology Cell Counters, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 28: Haematology Cell Counters, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 29: Haematology, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 30: Haematology, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010; Table 31: Histology And Cytology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 32: Histology And Cytology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 33: Histology And Cytology, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 34: Histology And Cytology, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010; Table 35: Immuno Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 36: Immuno Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 37: Disease Specific Immunochemistry, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 38: Disease Specific Immunochemistry, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 39: Drugs of Abuse / Toxicology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 40: Drugs of Abuse / Toxicology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 41: Endocrinology Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 42: Endocrinology Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 43: Therapeutic Drug Monitoring, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 44: Therapeutic Drug Monitoring, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 45: Immunochemistry Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 46: Immunochemistry Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 47: Immuno Chemistry, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 48: Immuno Chemistry, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010; Table 49: Infectious Immunology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 50: Infectious Immunology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 51: Infectious Immunology, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 52: Infectious Immunology, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010; Table 53: Microbiology Culture, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 54: Microbiology Culture, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 55: Microbiology Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 56: Microbiology Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 57: Microbiology Culture, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 58: Microbiology Culture, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010; Table 59: USD to Local Currency, United Arab Emirates, Average Actual Rate 2003-2010
1.2 List of Figures: Figure 1: In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, 2003-2017; Figure 2: In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, Historic, 2003-2010; Figure 3: In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, Forecast, 2010-2017; Figure 4: In Vitro Diagnostics, United Arab Emirates, Company share (%), 2010; Figure 5: Clinical Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 6: Clinical Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 7: Clinical Chemisty Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 8: Clinical Chemisty Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 9: Urine Analysis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 10: Urine Analysis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 11: Clinical Chemistry, United Arab Emirates, Company share (%), 2010; Figure 12: Genetic Testing, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 13: Genetic Testing, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 14: Genetic Testing, United Arab Emirates, Company share (%), 2010; Figure 15: Haematology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 16: Haematology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 17: Haematology Reagents, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 18: Haematology Reagents, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 19: Immunohaematology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 20: Immunohaematology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 21: Haemostasis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 22: Haemostasis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 23: Haematology Rapid Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 24: Haematology Rapid Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 25: Haematology Cell Counters, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 26: Haematology Cell Counters, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 27: Haematology, United Arab Emirates, Company share (%), 2010; Figure 28: Histology And Cytology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 29: Histology And Cytology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 30: Histology And Cytology, United Arab Emirates, Company share (%), 2010; Figure 31: Immuno Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 32: Immuno Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 33: Disease Specific Immunochemistry, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 34: Disease Specific Immunochemistry, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 35: Drugs of Abuse / Toxicology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 36: Drugs of Abuse / Toxicology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 37: Endocrinology Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 38: Endocrinology Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 39: Therapeutic Drug Monitoring, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 40: Therapeutic Drug Monitoring, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 41: Immunochemistry Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 42: Immunochemistry Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 43: Immuno Chemistry, United Arab Emirates, Company share (%), 2010; Figure 44: Infectious Immunology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 45: Infectious Immunology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 46: Infectious Immunology, United Arab Emirates, Company share (%), 2010; Figure 47: Microbiology Culture, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 48: Microbiology Culture, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 49: Microbiology Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 50: Microbiology Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 51: Microbiology Culture, United Arab Emirates, Company share (%), 2010; Figure 52: Global Markets Direct Methodology

More United Arab Emirates Reports

D&B Country RiskLine Report: The United Arab Emirates by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: The United Arab Emirates by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report United Arab Emirates January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

United Arab Emirates: Country Profile by MarketLine
INTRODUCTION This report provides a detailed analysis on the United Arab Emirates (UAE), providing an overview of its political, economic and business environment, represented both textually ...

Country Insight - United Arab Emirates Q3 2006 Report by Noozz Research
This Noozz Research Report offers a valuable perspective upon developments in the UAE marketplace. This report contains the latest analysis on the political and economic ...

See all reports like this >>

United Arab Emirates In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017

Share this report

Other tasks

Research Assistance

Related Markets

Hematology & Oncology Reports

Free Alert Me service